87987-99-3Relevant academic research and scientific papers
Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines
Kaizerman, Jacob A.,Aaron, Wade,An, Songzhu,Austin, Richard,Brown, Matt,Chong, Angela,Huang, Tom,Hungate, Randall,Jiang, Ben,Johnson, Michael G.,Lee, Gary,Lucas, Brian S.,Orf, Jessica,Rong, Minqing,Toteva, Maria M.,Wickramasinghe, Dineli,Xu, Guifen,Ye, Qiuping,Zhong, Wendy,McMinn, Dustin L.
scheme or table, p. 4607 - 4610 (2010/10/02)
Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metab
ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING
-
Page/Page column 74, (2009/04/25)
The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
New synthesis of pyrido[2,3-d] and [3,2-d]oxazines
Fahmy, Amin F.,Sauer, Juergen,Youssef, Mohamed Salah K.,Halim, Mohamed Said Abdel,Hassan, Mamdouh A.
, p. 2871 - 2886 (2007/10/03)
N-Hydroxyquinolinimide 1 reacts with each of aromatic arnines, hydrazine hydrate and aromatic hydrocarbons to give arylcarbamoyl pyridines 2, pyrrolopyridines 3, pyridopyridazines 4 and pyridooxazinones 5 and 6. The heterocycles 5 and 6 can be transformed
